NASDAQ:BRNS - US91864C1071 - ADR
Taking everything into account, BRNS scores 3 out of 10 in our fundamental rating. BRNS was compared to 549 industry peers in the Biotechnology industry. While BRNS has a great health rating, there are worries on its profitability. BRNS has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.94% | ||
ROE | -56.48% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -1.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 9.18 | ||
Quick Ratio | 9.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.18
-0.01 (-0.42%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.21 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.42 | ||
P/tB | 0.51 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -45.94% | ||
ROE | -56.48% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 9.2% | ||
Cap/Sales | 3.93% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 9.18 | ||
Quick Ratio | 9.18 | ||
Altman-Z | -1.9 |